← Eichor
Condition: Solid Tumor Cancer Treatment With Immunotherapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Solid Tumor Cancer Treatment With Immunotherapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibi
Phase N/A · 6 location(s) · Shantou University Medical College · NCT07357636Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07510815BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Immunotherapy With Adaptive Pulse Radiotherapy in Solid Tumors
Phase 2 · 1 location(s) · Samsung Medical Center · NCT07381231Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589530Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07641023Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Phase 2 · 7 location(s) · Centre Leon Berard · NCT02029001A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT05911464A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Phase 1 · 11 location(s) · Compugen Ltd · NCT06759649Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Phase 1 · 11 location(s) · BioNTech SE · NCT06750185Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a
Phase 1/Phase 2 · 6 location(s) · Phanes Therapeutics · NCT05431270VSV-02 Compassionate Use in Advanced Solid Tumors
Phase 1 · 1 location(s) · The First Affiliated Hospital of Xinxiang Medical College · NCT07260591ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Phase 1/Phase 2 · 21 location(s) · Immatics US, Inc. · NCT03686124Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 57 location(s) · Amgen · NCT04221542A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
Phase 1 · 1 location(s) · Guangzhou FineImmune Biotechnology Co., LTD. · NCT06716619Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy
NA · 1 location(s) · Centre Oscar Lambret · NCT05223608Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · Chuangzhen Chen · NCT07071103GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Phase 1/Phase 2 · 12 location(s) · GI Innovation, Inc. · NCT04977453Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589543AIMS Cancer Outcomes Study
Phase N/A · 1 location(s) · Advanced Integrative Medical Science Institute · NCT04495790Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional
Phase 1/Phase 2 · 11 location(s) · GI Innovation, Inc. · NCT05824975A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Tr
Phase 1 · 5 location(s) · Abalos Therapeutics GmbH · NCT07231458Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
Phase 1/Phase 2 · 1 location(s) · China-Japan Friendship Hospital · NCT06173219SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid
Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT06936748Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Act
Phase 1 · 6 location(s) · Jun Zhou · NCT07584954Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07502287VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · 15 location(s) · VM Oncology, LLC · NCT03556228Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589517
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.